Paratek Pharmaceuticals (FRA:N4CN) Other Long Term Assets : €34.6 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Other Long Term Assets?

Paratek Pharmaceuticals's other long-term assets for the quarter that ended in Jun. 2023 was €34.6 Mil.

Paratek Pharmaceuticals's quarterly other long-term assets increased from Dec. 2022 (€30.7 Mil) to Mar. 2023 (€34.3 Mil) and increased from Mar. 2023 (€34.3 Mil) to Jun. 2023 (€34.6 Mil).

Paratek Pharmaceuticals's annual other long-term assets increased from Dec. 2020 (€7.3 Mil) to Dec. 2021 (€25.1 Mil) and increased from Dec. 2021 (€25.1 Mil) to Dec. 2022 (€30.7 Mil).

Paratek Pharmaceuticals Other Long Term Assets Historical Data

The historical data trend for Paratek Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Other Long Term Assets Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Long Term Assets

Get a 7-Day Free Trial

0.40

2.84

7.34

25.12

30.65

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Other Long Term Assets	Get a 7-Day Free Trial															31.25	33.69	30.65	34.32	34.65

Paratek Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Paratek Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals Headlines

No Headlines